Plexāā accelerates plans to Launch BLOOM⁴³ in the U.S. at Texas Medical Center
November 2024 – Houston, TX – Plexāā, a pioneering UK MedTech company, is set to enter the U.S. market in 2025 with its groundbreaking medical device, BLOOM⁴³. The launch will mark a significant milestone in the company’s journey as it works to revolutionise post-surgical outcomes for breast surgery patients.
As one of the select participants in a prestigious six-month accelerator program by Innovate UK, Plexāā earned its place in the Texas Medical Center Innovation Factory Global Incubator Program. The program brings together some of the UK’s most promising HealthTech innovators, preparing them for success in the highly dynamic U.S. healthcare market.
During the program, Plexāā showcased BLOOM⁴³, earning recognition for its innovative approach to preventing wound-healing complications from breast surgeries and discussing applications for other surgical needs with key opinion leaders.
The accelerator culminated at the Envision Innovation Summit in Houston, where Plexāā’s Chief Operating Officer, Gaele Lalahy, presented the company’s ambitious plans for BLOOM⁴³’s U.S. launch. Held in one of the world’s largest medical hubs, the Envision Conference highlighted Houston’s reputation as a global leader in HealthTech innovation.
“Wherever we turned, the reception to BLOOM⁴³ and our vision for creating a world-class patient experience around surgery was overwhelmingly positive,” said Lalahy.
Plexāā shared the cohort spotlight with other groundbreaking innovators tackling critical health challenges, including AI-driven breast cancer screening, non-drug solutions for weight loss, Alzheimer’s and dementia therapies, and AR-assisted stroke rehabilitation.
“Being part of this extraordinary group has been a privilege,” said Dr. Saahil Mehta, Plastic Surgeon and Founder of Plexāā . “We are grateful for the advice and collaboration shared among the cohort, and for the support of Innovate UK, the Texas Medical Center Innovation Factory, and our mentors, who have helped refine our U.S. market entry strategy.”
With an eye towards 2025, Plexāā is ready to significantly impact the U.S. HealthTech landscape, driven by a commitment to improving surgical outcomes and elevating patient care standards.
About Plexāā
Plexāā is a pioneering UK MedTech company focused on improving surgical outcomes through innovative solutions. Their flagship device, BLOOM⁴³ enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect 1 in 3 women undergoing breast surgery.
BLOOM⁴³ is the world’s first fully wearable device worn next to the skin before breast surgery. By gently warming the area to stimulate the release of Heat Shock Proteins (HSPs). These naturally occurring proteins cause the release of carbon monoxide into the tissue which vasodilates the blood vessels and improves the blood flow to the skin. This improved blood flow primes the skin to heal and has been shown to prevent wound healing complications in proof-of-concept clinical trials.
Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes.
Media Contact:
